
UNC926 hydrochloride
CAS No. 1782573-49-2
UNC926 hydrochloride( —— )
Catalog No. M23797 CAS No. 1782573-49-2
UNC926 hydrochloride is a?methyl-lysine (Kme) reader domain?inhibitor.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 272 | In Stock |
![]() ![]() |
10MG | 408 | In Stock |
![]() ![]() |
25MG | 672 | In Stock |
![]() ![]() |
50MG | 945 | In Stock |
![]() ![]() |
100MG | 1278 | In Stock |
![]() ![]() |
500MG | 2547 | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameUNC926 hydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionUNC926 hydrochloride is a?methyl-lysine (Kme) reader domain?inhibitor.
-
DescriptionUNC926 hydrochloride is a?methyl-lysine (Kme) reader domain?inhibitor.
-
In VitroUNC926 also exhibits a low micromolar affinity for the close homolog, L3MBTL3 ( IC50 of 3.2 μM), with a decrease in affinity for the other MBT domains and no binding to CBX7.UNC926 (1-25 μM) inhibits binding of the 3xMBT domain to H4K20me1.UNC926 inhibits the association of L3MBTL13xMBT with the appropriate histonepeptides in a dose-dependent manner. UNC926 does not have an effect on the binding of 53BP1 to H4K20me1, demonstrating specificity of UNC926 for L3MBTL1 over 53BP1.
-
In Vivo——
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetEpigenetic Reader Domain
-
RecptorL3MBTL1|L3MBTL3|L3MBTL4
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1782573-49-2
-
Formula Weight373.72
-
Molecular FormulaC16H22BrClN2O
-
Purity>98% (HPLC)
-
SolubilityDMSO:150 mg/mL?(444.77 mM)
-
SMILESO=C(C1=CC=CC(Br)=C1)N2CCC(N3CCCC3)CC2.[H]Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Herold JM, et al. Structure-activity relationships of methyl-lysine reader antagonists. MedChemComm. 2012;3(45):45-51.
molnova catalog



related products
-
Pocenbrodib
Pocenbrodib (FT-7051) is a potent inhibitor of the bromodomain of the CBP/p300 family with potential antitumour activity and is palatable for cancer research.
-
GSK620
GSK620 is a pan-BD2 inhibitor, which shows an anti-inflammatory phenotype in human whole blood with excellent broad selectivity, developability, and in vivo oral pharmacokinetics.
-
dCBP-1
dCBP-1 is a chemical degrader of p300/CBP. dCBP-1 hijacks the E3 ubiquitin ligase CRBN for selective degradation of p300/CBP. Degradation of p300/CBP by dCBP-1 leads to effective multiple myeloma cell killing.